Page last updated: 2024-08-24

tenofovir and Hematologic Malignancies

tenofovir has been researched along with Hematologic Malignancies in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Chang, WY; Chen, DS; Chen, PJ; Cheng, PN; Chiu, FW; Chiu, YC; Hsu, YC; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC; Yang, SS1
Chen, FY; Cheng, Z; Huang, HH; Shi, KQ; Van Poucke, S; Zhang, MY; Zheng, JN; Zheng, MH; Zhu, GQ1

Reviews

1 review(s) available for tenofovir and Hematologic Malignancies

ArticleYear
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
    Expert review of anti-infective therapy, 2017, Volume: 15, Issue:5

    Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hematologic Neoplasms; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Lamivudine; Organophosphonates; Survival Analysis; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Activation

2017

Other Studies

1 other study(ies) available for tenofovir and Hematologic Malignancies

ArticleYear
High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy.
    The Journal of infectious diseases, 2020, 09-14, Volume: 222, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antiviral Agents; DNA, Viral; Female; Guanine; Hematologic Neoplasms; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Failure; Male; Middle Aged; Recurrence; Retrospective Studies; Risk Factors; Rituximab; Tenofovir; Viral Load; Virus Activation; Withholding Treatment; Young Adult

2020